# Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Source: https://onco.cc/trials/nct03228277/  
OnCo record `nct03228277` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olmutinib in Non-small-cell lung cancer, run by Konkuk University Medical Center, completed.

## Summary

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA is a phase 2 interventional study registered as NCT03228277 by Konkuk University Medical Center, with 25 participants recorded, started 2017-07-17 and reaching its primary completion in 2018-07-31. Interventions recorded: Olmutinib. Conditions recorded: Non Small Cell Lung Cancer.

Linked to the drug Olmutinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03228277
- Phase: 2
- Setting: Phase II, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy of Olmutinib(Olita®) in Patients With NSCLC Who Harboring T790M Mutation Confirmed Using DNA Extracted From Extracellular Vesicles in Bronchoalveolar Lavage Fluid
- Sponsor: Konkuk University Medical Center
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT03228277: https://clinicaltrials.gov/study/NCT03228277

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Olmutinib](https://onco.cc/drugs/olmutinib/)

---
JSON: https://onco.cc/api/v1/entities/nct03228277.json